Lesson plan
Cleminorexton
Cleminorexton ( ; former developmental code name ORX750) is an orexin OX 2 receptor agonist which is under development for the treatment of narcolepsy and idiopathic hypersomnia. It is taken orally. The drug was originated by Orexia, was subsequently developed by Centessa Pharmaceuticals, and is now being developed by Eli Lilly and Company. As of November 2025, it is in phase 2 clinical trials for narcolepsy and idiopathic hypersomnia.
Article summary
Cleminorexton ( ; former developmental code name ORX750) is an orexin OX 2 receptor agonist which is under development for the treatment of narcolepsy and idiopathic hypersomnia. It is taken orally. The drug was originated by Orexia, was subsequently developed by Centessa Pharmaceuticals, and is now being developed by Eli Lilly and Company. As of November 2025, it is in phase 2 clinical trials for narcolepsy and idiopathic hypersomnia.
Key claims
No claims recorded.
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
No sources recorded.
Key claims and bibliography are generated from the same tracked claims and sources as the article page.